After Another Covid Vaccine Delay, Novavax’s Opportunity Is Shrinking
Company Highlights Global Unmet Demand
Executive Summary
Novavax’s timelines are slipping once again, giving frontrunners Pfizer and Moderna the chance to consolidate their dominance in the market.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast episode of Five Must-Know Things, hear about issues surrounding the proposed IP waiver for coronavirus vaccines, a trial delay for Novavax’s COVID-19 vaccine, an ICER review of multiple myeloma drugs and Galapagos’ efforts to refocus its R&D pipeline.
Novavax Could Be The Next Biotech Winner In COVID-19 Vaccines
After years of setbacks, Novavax is on the cusp of success with its COVID-19 vaccine - but a rapid scale up of manufacturing and commercial operations will be a huge challenge.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.